Archive | Conferences

Neoadjuvant T-VEC May Reduce Recurrence in Operable Melanoma

Source: OncLive, July 2019 Neoadjuvant treatment with the oncolytic immunotherapeutic agent talimogene laherparepvec (T-VEC; Imlygic) led to significant improvement in 1-year recurrence-free survival (RFS) for patients with resectable advanced melanoma compared with surgery alone, a randomized trial showed.1 At 1 year, 33.5% of patients who received preoperative T-VEC plus surgery remained recurrence free, as compared […]

Read the full story

Posted in Melanoma News, Health Professionals, Conferences

Dabrafenib/Trametinib Combo Provides Lasting Control for BRAF V600-Mutant Metastatic Melanoma

Source: OncLive, July 2019 Five years out, one-third of patients with unresectable or metastatic BRAF V600-mutant melanoma remained alive following treatment with dual targeted therapy with dabrafenib (Tafinlar) plus trametinib (Mekinist), and 1 in 5 remained alive without progression, according to an analysis COMBI-d and COMBI-v trials reported at the 2019 ASCO Annual Meeting.1 Pooled data from […]

Read the full story

Posted in Melanoma News, Health Professionals, Conferences

ASCO 2019: T-VEC shows improved survival over cytokine therapy in patients with melanoma

Source: ECancer News, July 2019 Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma at Roswell Park Comprehensive Cancer Center, led research on the immunotherapy T-VEC, or talimogene laherparepvec, to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Dr. Puzanov is senior author […]

Read the full story

Posted in Melanoma News, Health Professionals, Conferences

ASCO 2019: T-VEC shows improved survival over cytokine therapy in patients with melanoma

Source: ECancer News, July 2019 Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma at Roswell Park Comprehensive Cancer Center, led research on the immunotherapy T-VEC, or talimogene laherparepvec, to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Dr. Puzanov is senior author […]

Read the full story

Posted in Melanoma News, Health Professionals, Conferences